Genomic signatures in non-small-cell lung cancer: Targeting the targeted therapies

Current Oncology Reports

Volumn 8, Issue 4, 2006, Pages 252-257

  Dressman, Holly K ^a   Bild, Andrea ^b   Garst, Jennifer ^b   Harpole Jr , David ^b   Potti, Anil ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BRONCHUS CARCINOID; CANCER GENETICS; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION; GENE TARGETING; GENETIC SUSCEPTIBILITY; GENOMICS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MICROARRAY ANALYSIS; MOLECULAR GENETICS; PREDICTION; PROGNOSIS; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS;

EID: 33745657609     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0029-1     Document Type: Article

References (28)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-643.
2. Minna JD, Roth JA, Gazdar AF: Focus on lung cancer. Cancer Cell 2002, 1:49-52.
3. Landit SH, Murry T, Bolden S, et al.: Cancer statistics 1999. CA Cancer J Clin 1999, 49:8-31.
4. Cancer Facts & Figures 2004. Atlanta, GA: American Cancer Society; 2004.
5. Alizadeh AA, Eisen MB, Davis BE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
6. van't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
7. Beer DG, Kardia SL, Huang CC, et al.: Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
8. Ramaswamy S, Ross KN, Lander ES, et al.: A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
9. Yeoh EJ, Ross ME, Shurtleff SA, et al.: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gent expression profiling. Cancer Cell 2002, 1:133-143.
10. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002, 21:6877-6883.
11. D'Amico, TA, Aloia, T, Moore, MB, et al.: Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 2000, 69:882-886.
12. Nelson, HH, Christiani DC, Mark EJ, et al.: Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999, 91:2032-2038.
13. de Perrot M, Licker M, Bouchardy C, et al.: Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000, 119:21-26.
14. Sandler AB, Gray R, Brahmer J, et al.: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [abstract]. J Clin Oncol 2005, Proc ASCO 2005, 23(16S):4.
15. Mountain CF: Lung cancer staging classification. Clin Chest Med 1993, 14:43-53.
16. Sandusky GE, Mintze KS, Pratt SE, et al.: Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002, 41:65-74.
17. Huang E, Cheng SH, Dressman H, et al.: Gene expression predictors of breast cancer outcomes. Lancet 2003, 361:1590-1596.
18. Garber ME, Troyanskaya OG, Schluens K, et al.: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci 2001, 98:13784-13789.
19. Bhattacharjee A, Richards WG, Staunton J, et al.: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci 2001, 98:13790-13795.
20. Wigle DA, Jurisica I, Radulovich N, et al.: Molecular profiling of non small cell lung cancer and correlation with disease-free survival. Cancer Res 2002, 62:3005-3008.
21. Gordon GJ, Jensen RV, Hsiao LL, et al.: Translation of microarray data into clinically relevant cancer diagnostic tests using gone expression ratios in lung cancer and mesothelioma. Cancer Res 2002, 62:4963-4967.
22. Sugita M, Geraci M, Gao B, et al.: Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 2002, 62:3971-3979.
23. Welsh JB, Sapinoso LM, Kern SG, et al.: Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum, Proc Natl Acad Sci 2003, 100:3410-3415.
24. Park IW, Wistuba II, Maitra A, et al.: Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999, 91:1863-1868.
25. Powell CA, Spira A, Derti A, et al.: Gene expression in lung adenocarcinomas of smokers and non-smokers. Am J Respir Cell Mol Biol 2003, 29:157-162.
26. Johnson SK, Kerr KM, Chapman AD, et al.: Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000, 27:27-35.
27. Moran CJ, Arenberg DA, Huang CC, et al.: RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002, 8:3803-3812.
28. Bild A, Yao, G, Chang JT, et al.: Gene expression signatures of oncogenic pathway deregulation guide targeted therapy. Nature 2006, 459:353-357.